CardioSource WorldNews December 2014 | Page 8

For patients with nonvalvular atrial fibrillation (NVAF),

ONLY ELIQUIS
DELIVERS BOTH

The ONLY anticoagulant that demonstrated superiority in BOTH stroke/systemic
embolism and major bleeding vs warfarin.1

SUPERIOR

SUPERIOR

Based on
fewer major
bleeding* events
vs warfarin1

Risk reduction in
stroke/systemic
embolism
vs warfarin1
1.27%/year vs 1.60%/year; P=0.01
HR†=0.79 (95% CI,‡ 0.66, 0.95); 21% RRR§

PRIMARY EFFICACY OUTCOME

2.13%/year vs 3.09%/year; P<0.0001
HR=0.69 (95% CI, 0.60, 0.80); 31% RRR

PRIMARY SAFETY OUTCOME

Superiority to
warfarin was
primarily
attributable to
a reduction in
hemorrhagic stroke
and ischemic strokes
with hemorrhagic
conversion compared
to warfarin. Purely
ischemic strokes
occurred with similar
rates on both drugs.1

In another clinical
trial, AVERROES®,
ELIQUIS was
associated
with an increase
in major bleeding
compared to
aspirin that was not
statistically significant
(1.41%/year vs O.92%/
year, HR=1.54 [95% CI,
0.96, 2.45]; P=0.07).1

The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE, this occurred in
1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.
*Major bleeding was defined as clinically overt bleeding accompanied by one or more of the
following: bleeding that was fatal; bleeding that occurred in at least one critical site (critical
hcp.eliquis.com
sites included intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular
with compartment syndrome, retroperitoneal); a transfusion of 2 or more units of packed red
blood cells; or a decrease in hemoglobin of 2 g/dL or more.
Connect with us to learn more about
†
HR=hazard ratio; ‡CI=confidence interval; §RRR=relative risk reduction.
ELIQUIS and our NVAF clinical trial program.
ELIQUIS® and the ELIQUIS logo are trademarks of Bristol-Myers Squibb Company.
© 2014 Bristol-Myers Squibb Company. All rights reserved. 432US14BR01934-03-01 09/14